Millendo gains license to AstraZeneca PCOS drug candidate

6 January 2016

Millendo Therapeutics, a University of Michigan, USA, start-up company, announced an exclusive license agreement with Anglo-Swedish pharma major AstraZeneca (LSE: AZN) for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome (PCOS).

Millendo acquired global rights to develop and commercialize MLE4901 (previous code AZD4901), a Phase II neurokinin 3 receptor, in return for an undisclosed upfront payment to AstraZeneca an upfront payment, plus payments tied to development and commercial milestones. AstraZeneca is eligible to receive royalties on net product sales, and also took an undisclosed equity stake in Millendo. There are no approved therapies for PCOS, which affects up to 15% of women, the company noted.

Secures $62 million funding

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK